loading...

Quality of Life Disease Impact Scale–7 item scale (QDIS-7-item scale)

Ware JE

Distributed by Mapi Research Trust

ProQolid

Distributed by Mapi Research Trust

Basic description

Author Webinar: Mar 12 2020 @ 10 am EST

Missed the live webinar? Register here to watch the recording

Patient-Reported Outcomes Assessments: Spotlight on the Quality of Life Disease Impact Scale (QDIS®)

A new approach to improving patient-reported disease-specific quality of life measures: shorter, more clinically valid and standardized across conditions.

  • Published in 2015
  • Developed during the Computerized Adaptive Assessment of Disease Impact (DICAT) project supported by the NIH to generate a more comprehensive PRO measure of disease-specific impact, of which content and scoring could be standardized for comparison across different conditions
  • QDIS-7 is a fixed 7-item short-form derived from the 49-item QDIS full bank
  • Other versions exist: QDIS-CAT, QDIS-1, and QDIS-MCC
Authors

Ware JE

Copyright
Copyright © 2010-2019 John Ware Research Group, Inc. All rights reserved
Objective
To measure disease-specific Quality of Life (QoL) impact reported by chronically ill patients and to compare it across distinct conditions
Therapeutic area
  • Generic
Therapeutic indication

All

Type of Clinical Outcome Assessment (COA)
  • pro PRO
Original language(s)
  • English for the USA
Bibliographic reference(s) of the original questionnaire

Ware JE Jr, Gandek B, Guyer R, Deng N. Standardizing disease-specific quality of life measures across multiple chronic conditions: development and initial evaluation of the QOL Disease Impact Scale (QDIS®). Health Qual Life Outcomes. 2016 Jun 2;14:84. (Full article)

Deng N, Anatchkova MD, Waring ME, Han KT, Ware JE Jr. Testing item response theory invariance of the standardized Quality-of-life Disease Impact Scale (QDIS(®)) in acute coronary syndrome patients: differential functioning of items and test. Qual Life Res. 2015 Aug;24(8):1809-22. (PubMed abstract)

Ware JE Jr, Gandek B, Kulasekaran A, Guyer R. Evaluation of smoking-specific and generic quality of life measures in current and former smokers in Germany and the United States. Health Qual Life Outcomes. 2015 Aug 16;13:128 (Full-text article)

Access this questionnaire

All requests have to be submitted through our online request management:

  1. Log in or Register for free
  2. Submit your request (Tutorials are available on our FAQs)
  3. Our PROVIDE team will get back to you with the needed information and license agreement in a timely manner.

Fees may apply to your project.


Contact and conditions of use

Authors

Ware JE

Contact information

Mapi Research Trust
PROVIDE™
27 rue de la Villette
69003 Lyon
France
Phone: +33 (0)4 72 13 66 66

Conditions of use

All requests have to be submitted through our online request management:

  1. Log in or Register for free
  2. Submit your request (Tutorials are available on our FAQs)
  3. Our PROVIDE team will get back to you with the needed information and license agreement in a timely manner.

Fees may apply to your project.

Review copy

Examination copies can only be used for the limited purpose of examining the suitability of the Questionnaire for subsequent research and/or clinical use, and cannot be used in research or in clinical practice or distributed to others.
You are not authorized to modify, retype, translate, copy or otherwise duplicate the Questionnaire except with the further and prior written permission of Mapi Research Trust / the developers / copyright holders / distributors.

Languages

Original language(s)

  • English for the USA

Translations

The list of available translations is subject to constant changes and may not be exhaustive. It is provided for information only. Some recently produced translations may not be included in the list below yet. Please do check the status of available translations with Mapi Research Trust / the developers / copyright holders / distributors.

Also, the listed translations may not have undergone a full linguistic validation process and may require further work to be suitable for use in a study.

QDIS-7

Japanese for Japan
Spanish for the USA*
* Performed by Mapi

The author has selected Mapi/ICON Language Services as exclusive linguistic validation company to ensure the production of harmonized and consistent language versions.

For additional information on available translations of this instrument, or for a project involving new languages, please submit a request (tutorials available on our FAQs).

Conditions to translate

Commercial Users

Exclusive vendor for translation work for commercial users: Mapi/ICON Language Services

Academic Translation

If you wish to translate the questionnaire:

  1. Log in or Register for free
  2. Submit your request for translation online (Tutorials are available on our FAQs)
  3. Our PROVIDE team will send you a translation agreement along with Linguistic Validation Guidelines.

More information on translations

For information on, or permission to use the translations, please contact Mapi Research Trust

N.B.: MRT licenses and provides the Japanese translation to clients ONLY in the context of multi-national language projects.

For Japanese-language-only projects, licensing, providing and scoring of the Japanese translation is performed exclusively by Professor Shunichi Fukuhara (Kyoto University): MRT is not involved and clients should send their request directly to Pr Fukuhara at qol@sf-36.jp.

Member Access

Subscribe to PROQOLID to access to full information

Access to advanced descriptions of Clinical Outcome Assessments (COAs)

A question? Contact us